NexiumCare Company
Stay up to date with our latest product launches, partnerships, funding milestones, and industry recognition. We believe in transparency — our roadmap and progress are shared openly with our community.
NexiumCare closed a $45M Series B led by Andreessen Horowitz Bio Fund, bringing total funding to $68M. The investment will accelerate Nexi AI Scribe development, expand our specialty coverage, and grow our customer success team.
Our next-generation Nexi AI Scribe now supports 15+ specialties with 95% note accuracy. New features include real-time coding suggestions, automated quality measure capture, and multi-language support.
NexiumCare now offers direct, bidirectional lab integration with Quest Diagnostics — enabling electronic ordering and real-time results delivery for all customers at no additional cost.
We're proud to announce that over 1,000 independent practices now use NexiumCare as their primary EHR platform, representing 3,500+ providers across 48 states.
12 August, 2026
The investment will accelerate Nexi AI Scribe development
12 August, 2026
The investment will accelerate Nexi AI Scribe development
12 August, 2026
The investment will accelerate Nexi AI Scribe development
12 August, 2026
The investment will accelerate Nexi AI Scribe development
Start your free trial or talk to our team about how NexiumCare can help your practice.
